Cathepsin K generates enkephalin from β-endorphin: A new mechanism with possible relevance for schizophrenia

Neurochemistry International

Volumn 54, Issue 7, 2009, Pages 410-417

  Lendeckel, Uwe ^a,b   Kähne, Thilo ^a   Ten Have, Sara ^a   Bukowska, Alicja ^a   Wolke, Carmen ^a,b   Bogerts, Bernhard ^a   Keilhoff, Gerburg ^a   Bernstein, Hans Gert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Cathepsin; Endorphin; Enkephalin; Protease; Schizophrenia

Indexed keywords

BETA ENDORPHIN; CATHEPSIN K; ENKEPHALIN; HALOPERIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SCHIZOPHRENIA; THALAMUS MIDLINE NUCLEUS;

ADULT; ANTIPSYCHOTIC AGENTS; ARCUATE NUCLEUS; BETA-ENDORPHIN; BRAIN CHEMISTRY; CATHEPSINS; CELL LINE, TUMOR; ENKEPHALIN, METHIONINE; FEMALE; HALOPERIDOL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEURONS; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; RNA, MESSENGER; SCHIZOPHRENIA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 63149086605     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.01.011     Document Type: Article

References (39)

1. Abel T.W., and Rance N.E. Proopiomelanocortin gene expression is decreased in the infundibular nucleus of postmenopausal women. Brain Res. Mol. Brain Res. 69 2 (1999) 202-208
2. Aono J., Takahashi M., and Koida M. An assay method of brain enzyme carving β-endorphin into methionine enkephalin. Jpn. J. Pharmacol. 28 (1978) 930-932
3. Bernstein H.G., Henning H., Seliger N., Baumann B., and Bogerts B. Remarkable beta-endorphinergic innervation of human cerebral cortex as revealed by immunohistochemistry. Neurosci. Lett. 30 (1996) 33-36
4. Bernstein H.G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., Falkai P., and Bogerts B. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83 (1998) 867-875
5. Bernstein H.G., Baumann B., Danos P., Diekmann S., Bogerts B., Gundelfinger E.D., and Braunewell K.H. Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brain. J. Neurocytol. 28 (1999) 655-762
6. Bernstein H.G., Krell D., Emrich H.M., Baumann B., Danos P., Diekmann S., and Bogerts B. Fewer beta-endorphin expressing arcuate nucleus neurons and reduced beta-endorphinergic innervation of paraventricular neurons in schizophrenics and patients with depression. Cell. Mol. Biol. (2002) OL259-OL265 ((Noisy-le-grand). 48 Online Pub)
7. Bernstein H.G., Bukowska A., Dobrowolny H., Bogerts B., and Lendeckel U. Cathepsin K and schizophrenia. Synapse 61 4 (2007) 252-253
8. Bernstein H.G., Bogerts B., and Lendeckel U. Cathepsin K and metabolic abnormalities in schizophrenia. Arterioscler. Thromb. Vasc. Biol. 28 12 (2008) e163
9. Brix K., Dunkhorst A., Mayer K., and Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 90 (2008) 194-207
10. Chiellini C., Costa M., Novelli S.E., Amri E.Z., Benzi L., Bertacca A., Cohen P., Del Prato S., Friedman J.M., and Maffei M. Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. J. Cell. Physiol. 195 2 (2003) 309-321
11. Craddock N., O'Donovan M.C., and Owen M.J. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J. Med. Genet. 42 3 (2005) 193-204
12. Danos P., Baumann B., Krämer A., Bernstein H.G., Stauch R., Krell D., Falkai P., and Bogerts B. Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr. Res. 60 2-3 (2003) 141-155
13. Dean B., Crook J.M., Pavey G., Opeskin K., and Copolov D.L. Muscarinic 1and 2 receptor mRNA in the human caudate-putamen: no change in mRNA in schizophrenia. Mol. Psychiatry 5 (2000) 203-207
14. De Wied D., and Sigling H.O. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotoxicol. Res. 4 5-6 (2002) 453-468
15. Emrich H. Endorphins in psychiatry. Psychiatr. Dev. 2 (1984) 97-114
16. Fehér L.Z., Kálmán J., Puskás L.G., Gyülvészi G., Kitajka K., Penke B., Palotás M., Samarova E.I., Molnár J., Zvara A., Matin K., Bódi N., Hugyecz M., Pákáski M., Bjelik A., Juhász A., Bogáts G., Janka Z., and Palotás A. Impact of haloperidol and risperidone on gene expression profile in the rat cortex. Neurochem. Int. 47 4 (2005) 271-280
17. Funicello M., Novelli M., Ragni M., Vottari T., Cocuzza C., Soriano-Lopez J., Chiellini C., Boschi F., Marzola P., Masiello P., Saftig P., Santini F., St-Jacques R., Desmarais S., Morin N., Mancini J., Percival M.D., Pinchera A., and Maffei M. Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores. PLoS ONE 2 1 (2007) e683
18. Godat E., Lecaille F., Desmazes C., Duchene S., Weidauer E., Saftig P., Brömme D., Vandier C., and Lalmanach G. Cathepsin K: a cysteine protease with unique kinin-degrading properties. Biochem. J. 383 (2004) 501-506
19. Gos T., Günther K., Bielau H., Dobrowolny H., Mawrin C., Trübner K., Brisch R., Steiner J., Bernstein H.G., Jankowski Z., and Bogerts B. Suicide and depression in the quantitative analysis of glutamic decarboxylase-immunoreactive neuropil. F. Affect. Disord. 113 (2009) 45-55
20. Hui H., and Hui K.-S. A new type of neuron-specific aminopeptidase NAP-2 in rat brain synaptosomes. Neurochem. Int. 53 (2008) 317-324
21. Iizuka I., Sei Y., Weinberger D.R., and Straub R.E. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J. Neurosci. 27 (2007) 12390-12395
22. Kishimoto T., Watanabe K., Takeuchi H., Kikuchi T., Nakajima S., Shimada N., Yagi G., and Kashima H. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr. Res. 77 1 (2005) 113-115
23. Ko F., Tallerico T., and Seeman P. Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine. Synapse 60 2 (2006) 141-151
24. Koida M., Aono J., Takenaga K., Yoshimoto T., Kimura T., and Sakakibara S. A novel enzyme in rat brain converting β-endorphin into met-enkephalin: affinity chromatography and specificity. J. Neurochem. 33 (1979) 1233-1237
25. Küry P., Schroeter M., and Jander S. Transcriptional response to circumscribed cortical brain ischemia: spatiotemporal patterns in ischemic vs. remote non-ischemic cortex. Eur. J. Neurosci. 19 (2004) 1708-1720
26. Li Z., Kienetz M., Cherney M.M., James M.N.G., and Brömme D. The crystal and molecular structures of a cathepsin K: chondroitin sulfate complex. J. Mol. Biol. 383 (2008) 78-91
27. Margolis E.B., Lock H., Chefer V.I., Shippenberg T.S., Hjelmstad G.O., and Fields H.L. κ-Opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc. Natl. Acad. Sci. U.S.A. 103 8 (2006) 2938-2942
28. Mayhew M.H. A review of recent advances in stereology for quantifying neural structure. J. Neurocytol. 21 (1992) 313-328
29. Mosnaim A.D., Nguyen T.D., Puente J., and Wolf M.E. Degradation kinetics of methionine5-enkephalin by select brain areas from patients with chronic schizophrenia. Am. J. Ther. 15 2 (2008) 126-130
30. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
31. Purba J.S., Hoogendijk W.J., Hofman M.A., and Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 53 2 (1996) 137-143
32. Reed B., Bidlack J.M., Chait B.T., and Kreek M.J. Extracellular biotransformation of β-endorphin in rat striatum and cerebrospinal fluid. J. Neuroendocrinol. 20 (2008) 606-616
33. Tirupati S., and Chua L.E. Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas. Psychiatry 15 6 (2007) 470-473
34. Wiegant V.M., Ronken E., Kovacs G., and De Wied D. Endorphins and schizophrenia. Prog. Brain Res. 93 (1992) 433-453
35. Yamada Y., Esaki Y., and Mizutami T. Intracranial cavity volume can be accurately estimated from the weights of intracranial contents: confirmation by the dental plaster casting method. Neuropathol. Appl. Neurobiol. 25 (1999) 341-344
36. Yang C.R., Seamans J.K., and Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21 (1999) 161-194
37. Yang M., Sun J., Zhang T., Liu J., Zhang J., Shi M.A., Darakhshan F., Guerre-Millo M., Clement K., Gelb B.D., Dolgnov G., and Shi G.P. Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler. Thromb. Vasc. Biol. (2008) (Epub ahead of print)
38. Yasothornsrikul S., Greenbaum D., Medzihradszky K.F., Toneff T., Bundey R., Miller R., Schilling B., Petermann I., Dehnert J., Logvinova A., Goldsmith P., Neveau J.M., Lane W.S., Gibson B., Reinheckel T., Peters C., Bogyo M., and Hook V. Cathepsin L in secretary vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc. Natl. Acad. Sci. U.S.A. 100 16 (2003) 9590-9595
39. Zech M., and Bogerts B. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study. Acta Neuropathol. 68 1 (1985) 32-38